Baidu
map

美国临床医生最喜欢哪款多发性硬化症药物?诺华、默克还是Biogen的?

2019-11-22 不详 MedSci原创

尽管来自诺华、默克和Biogen的新型多发性硬化症药物今年已进入市场并被寄予厚望,但临床医生们对这些药物并不那么感兴趣。一位分析师说,反而是尚未批准的一种扩展用途的多发性硬化症(MS)疗法引起了"一致的兴趣"。

尽管来自诺华、默克和Biogen的新型多发性硬化症药物今年已进入市场并被寄予厚望,但临床医生们对这些药物并不那么感兴趣。一位分析师说,反而是尚未批准的一种扩展用途的多发性硬化症(MS)疗法引起了"一致的兴趣"。

五位MS医师告诉SVB Leerink分析师Geoffrey Porges的团队,最近进入MS领域的药物,包括Novartis的选择性1-磷酸鞘氨醇(S1P)受体调节剂Mayzent,默克的Mavenclad(cladribine,克拉屈滨片剂)和Biogen的新型口服富马酸酯Vumerity,与现有产品本质上"没有区别"。

"这些评论表明,这些新产品可能只会获得有限的市场份额,并且不能证明该产品比该类别原有药物具有明显的价格优势," Porges在周五给客户的一份报告中说。

令人惊讶的是,诺华的抗癌药物全人源化靶向CD20单克隆抗体Arzerra(ofatumumab)获得了广泛好评,但尚未获得多发性硬化症的批准。SVB Leerink认为,医生们认为它具有罗氏的"Ocrevus的类似功效",并且具有自我管理的便利性。

根据早期的Evaluate Pharma预测,Mayzent在3月下旬获得FDA批准,用于治疗复发型MS,包括活动性继发性进行性MS和复发缓解型MS,在2024年的销售额可能达到130亿美元。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2020-03-27 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2020-05-24 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-24 qjddjq
  7. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-22 lovetcm

    各家药物越来越相似

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 22 09:58:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918933, encodeId=cbfe1918933cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 27 15:58:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890075, encodeId=dc6018900e5cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun May 24 12:58:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554800, encodeId=181915548003d, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 10:58:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375672, encodeId=9e413e5672fc, content=各家药物越来越相似, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 21:12:10 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375669, encodeId=d2d83e5669ae, content=西方MS多, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 22 20:31:38 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-22 lovetcm

    西方MS多

    0

相关资讯

抗高血压药的用药禁忌,临床医生须谨记

高血压病是中老年人常见的一种慢性疾病,除了改善患者的饮食习惯及生活方式外,应使用抗高血压药物进行长期或终生治疗。抗高血压药物种类较多,如应用不当不仅达不到治疗目的,更有可能引起多种副作用或不良反应。下面就来介绍下临床上常用的一线降压药的用药禁忌及注意事项。敲黑板,划重点!一、利尿剂其降压机制是利钠排水,使高血容量负荷降低而发挥降压作用。包括袢利尿剂、噻嗪类利尿剂以及保钾利尿剂。代表药物有氢氯噻嗪、

Biochemia Medica:临床医生对关键风险结果的意见:在克罗地亚一家三级医院的调查

如果每个实验室修改其关键结果报告实践程序,则以反映其患者群体的临床需求。

王拥军教授:从临床医生到临床科学家的关键几步

有人把医生依照能力水平分为三个层次:合格的临床医生、杰出的学科带头人和卓越的临床科学家,可见临床科学家应该是很多医生努力的终极目标。首都医科大学附属北京天坛医院王拥军教授及其团队连续六年是国际卒中领域顶级杂志《stroke》收录论文最多的单中心,他们的临床研究质量和数量均达到国际一流水准,得到国内外同行的高度认可。近日,他领衔打造了临床科学家训练营,旨在培训临床医生获得更高的临床科研能力。对于

临床医生要不要做科研?在黄晓军看来这不是问题

临床医生要不要做科研?这是个问题。但在北京大学人民医院黄晓军看来,这不是个问题。

张力教授:临床医生除了看好病,科研也不能落下

由北京白求恩公益基金会主办的“白求恩·中青年医生优才培养计划项目”科研培训上海站隆重召开。本次培训课程围绕临床医生在临床研究创新思路的寻找、研究设计、数据库建设、统计分析、文章写作与最终科研成果发表等一系列各方面存在的误区,可能遇到的问题,结合实例展开整个课程,以期为肺癌领域临床专家解决科研道路上的实际问题。

是否所有ICU临床医生都需要定期进行倦怠测试? 是

ICU的入院是非计划的紧急情况,需要ICU专业人员迅速处理伴有不确定结果的复杂情况,当处理患者和家人医疗危机时,专业团队陷入了一种高度紧张和强烈情绪的复杂环境中,随着对高级维持生命治疗技术的要求日益提高,工作环境越来越复杂。越来越多的证据表明,ICU护士和医生的职业倦怠是这种不可避免的高压力工作环境要求的直接后果。严重的职业倦怠相关症状非常普遍,已有1/3的ICU护理人员和1/2的ICU被报道

Baidu
map
Baidu
map
Baidu
map